Reported 5 months ago
JiSheng Bio-Tech (7762) is a radioactive sterile drug manufacturer certified by the Ministry of Health and Welfare PIC/S GMP. It is the first publicly traded nuclear medicine company in Taiwan and has applied for registration on the OTC market, planning to enter the domestic capital market in the near future to further accelerate the development of its nuclear medicine products. Established in 2011, JiSheng Bio-Tech saw a significant turning point in its operations last year, with a 55.62% increase in revenue to NT$117 million, marking a new high in its history. The company focuses on the development of nuclear medicine products used in molecular imaging and international drug development, with a strong emphasis on brain-related diseases and cancer treatment using PET and SPECT radiopharmaceuticals.
Source: YAHOO